Background Immune-mediated necrotizing myopathy (IMNM) is a distinct entity with limited large-cohort data. We aimed to characterize clinico-serological features and treatment outcomes of anti-SRP, anti-HMGCR, and seronegative IMNM in a large Italian cohort. Methods Retrospective multicenter study of adults diagnosed with IMNM (224th ENMC criteria) across 14 Italian neuro- muscular centers between 2019 and 2022 was performed. Results We included 159 subjects (57% female, median age 62 years): 40 SRP+, 71 HMGCR+, 41 seronegative, and 7 untested. SRP+ more frequently presented with proximal upper limb weakness and axial involvement versus HMGCR+ (OR = 3.89, padj = 0.007, OR = 3.47, padj = 0.04) and seronegative (OR = 4.00, padj = 0.014, OR = 15.2, padj = 0.005). Lung involvement was higher in SRP+ (7.5%), vs none in HMGCR+ and 2.4% in seronegative (p=0.028). Extramuscular features were more frequent in HMGCR+ (OR = 3.78, p = 0.019, padj = 0.057). SRP+ had higher odds of loss of motor independence (OR=4.22, padj =0.011) and relapse (OR = 14.4, padj = 0.010) than HMGCR+. Seronegative had better functional outcomes than SRP+ (p=0.047). Cancer associated myositis predicted worse disability (OR = 6.93, p = 0.0044). Overall, 71.7% improved with corticosteroids (OR=3.83, padj =0.01) and immunosuppressants (OR=2.296, padj =0.037), without serotype differences. CK decreased in 81.8% and normalized in 40.3% of patients; ΔCK was associated with improve- ment (p=0.017), clinical remission (p=0.002) and correlated with post-treatment functional scores (R=0.19, p= 0.044). Conclusion Subtype-specific differences and prognostic factors emerge. Exploratory functional assessment and ΔCK may capture treatment response in real-world settings.
Immune‐mediated necrotizing myopathies: clinico‐serological features and treatment outcomes of a large Italian cohort of patients / Bonanno, S., Salvi, E., Cheli, M., Salerno, F., Lucchini, M., Cicia, A., Carlomagno, V., Lauletta, A., Tufano, L., Girolamo, F., Nicolini De Gaetano, L., Fornaro, M., Pancheri, E., Zaottini, F., Faedo, E., Rovere Querini, P., De Lorenzo, R., Scarlato, M., Bottazzi, F., Riguzzi, P., et al.. - In: JOURNAL OF NEUROLOGY. - ISSN 1432-1459. - 273:9(2026). [10.1007/s00415-026-14089-1]
Immune‐mediated necrotizing myopathies: clinico‐serological features and treatment outcomes of a large Italian cohort of patients
Antonio Lauletta;Laura Tufano;Giovanni Antonini;Matteo Garibaldi;
2026
Abstract
Background Immune-mediated necrotizing myopathy (IMNM) is a distinct entity with limited large-cohort data. We aimed to characterize clinico-serological features and treatment outcomes of anti-SRP, anti-HMGCR, and seronegative IMNM in a large Italian cohort. Methods Retrospective multicenter study of adults diagnosed with IMNM (224th ENMC criteria) across 14 Italian neuro- muscular centers between 2019 and 2022 was performed. Results We included 159 subjects (57% female, median age 62 years): 40 SRP+, 71 HMGCR+, 41 seronegative, and 7 untested. SRP+ more frequently presented with proximal upper limb weakness and axial involvement versus HMGCR+ (OR = 3.89, padj = 0.007, OR = 3.47, padj = 0.04) and seronegative (OR = 4.00, padj = 0.014, OR = 15.2, padj = 0.005). Lung involvement was higher in SRP+ (7.5%), vs none in HMGCR+ and 2.4% in seronegative (p=0.028). Extramuscular features were more frequent in HMGCR+ (OR = 3.78, p = 0.019, padj = 0.057). SRP+ had higher odds of loss of motor independence (OR=4.22, padj =0.011) and relapse (OR = 14.4, padj = 0.010) than HMGCR+. Seronegative had better functional outcomes than SRP+ (p=0.047). Cancer associated myositis predicted worse disability (OR = 6.93, p = 0.0044). Overall, 71.7% improved with corticosteroids (OR=3.83, padj =0.01) and immunosuppressants (OR=2.296, padj =0.037), without serotype differences. CK decreased in 81.8% and normalized in 40.3% of patients; ΔCK was associated with improve- ment (p=0.017), clinical remission (p=0.002) and correlated with post-treatment functional scores (R=0.19, p= 0.044). Conclusion Subtype-specific differences and prognostic factors emerge. Exploratory functional assessment and ΔCK may capture treatment response in real-world settings.| File | Dimensione | Formato | |
|---|---|---|---|
|
Bonanno_Immune_2026.pdf
solo gestori archivio
Note: Bonanno_Immune_2026
Tipologia:
Licenza (contratto editoriale)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
1.27 MB
Formato
Adobe PDF
|
1.27 MB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


